Notes and Loan Payable (Details Textual) - USD ($)			1 Months Ended							3 Months Ended		6 Months Ended
	May 14, 2018	Dec. 15, 2017	Jul. 26, 2018	Jun. 15, 2018	May 31, 2018	May 28, 2018	May 18, 2018	May 09, 2018	Dec. 31, 2017	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Jun. 15, 2017	Dec. 31, 2016	Feb. 28, 2014	Mar. 31, 2012
Notes and Loans Payable [Line Items]
Loans Payable										$ 510,000		$ 510,000
Interest Expense										281,000	$ 2,142,000	346,000	$ 3,197,000
Loss Contingency, Damages Sought, Value								$ 2,800,000
Gain (Loss) on Extinguishment of Debt						$ 181,000				181,000	0	181,000	0
Proceeds From Convertible Notes Two												2,007,000	0
Warrants Not Settleable in Cash, Fair Value Disclosure	$ 91,000
Amortization of Debt Issuance Costs and Discounts					$ 865,000
Number of Warrant Issued	474,667
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.47
Liquidated Damages										$ 1,112,000	0	1,112,000	0
Proceeds from Notes Payable												$ 3,000,000
Minimum Bid Price										$ 1.00		$ 1.00
Mandatory Default Amount Percentage on Principal										40.00%		40.00%
Deemed Dividend										$ (5,599,000)	$ 0	$ (5,599,000)	0
Series E Warrants [Member]
Notes and Loans Payable [Line Items]
Warrant, Exercise Price, Decrease							$ 0.30
Deemed Dividend										424,000		424,000
Series E Preferred Stock [Member]
Notes and Loans Payable [Line Items]
Preferred Stock, Convertible, Conversion Price, Decrease							$ 0.30
Deemed Dividend										5,175,000		$ 5,175,000
Meda Pharma SARL [Member]
Notes and Loans Payable [Line Items]
Fixed Consideration Payable in Installments Over Three Year Period description												In conjunction with the Asset Purchase Agreement with Meda described in Note 6, we agreed to pay a fixed consideration of $5.0 million, payable in installments over a three-year period as follows: (i) $1.5 million on the earlier of: (1) the successful transfer to us of all of the marketing authorizations for the product or (2) the date which is six months after the Completion Date (as defined in the Asset Purchase Agreement); (ii) $1.5 million on the first anniversary of the Completion Date; (iii) $1.0 million on the second anniversary of the Completion Date; and (iv) $1.0 million on the third anniversary of the Completion Date.
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt										3,600,000		$ 3,600,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt										900,000		900,000
Payments for Asset Purchase Agreement Amount		$ 1,500,000		$ 1,500,000
Debt Instrument, Interest Rate, Stated Percentage														15.00%
Mablife Notes Payable [Member]
Notes and Loans Payable [Line Items]
Notes Payable															$ 100,000
Interest Expense												0	$ 0
Loss Contingency, Damages Sought, Value									$ 205,000
Asset Acquisition Payable [Member]
Notes and Loans Payable [Line Items]
Interest Expense												65,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt										3,000,000		3,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt										1,400,000		1,400,000
Debt Instrument, Unamortized Discount										649,000		649,000
Convertible Notes Two [Member]
Notes and Loans Payable [Line Items]
Debt Instrument, Face Amount	$ 2,781,000
Debt Instrument, Unamortized Discount	$ 556,000
Proceeds From Convertible Notes Two						$ 2,007,000
Debt Instrument Unamortized Discount Percentage	20.00%
Debt InstrumentPlacement Agent Fee Percentage					8.00%
Placement Agent Fee					$ 178,000
Other Placement Agent Fee					$ 40,000
Debt Instrument, Convertible, Conversion Price	$ 0.375
Debt Conversion Converted Instrument Maximum Shares to be Issued	6,397,456
Debt Instrument, Maturity Date, Description	The May 2018 Convertible Notes are due and payable upon the earlier of (a) November 18, 2018 and (b) the closing by of one or more subsequent financings with gross proceeds equal to at least $3,000,000 in the aggregate. The holders of the May 2018 Convertible Notes have the option to extend the maturity date of the notes through February 18, 2019. The May 2018 Convertible Notes represent senior indebtedness of the Company.
Interest Expense, Debt										$ 216,000		$ 216,000
Debt Instrument, Interest Rate, Stated Percentage					1.50%					19.99%		19.99%
Liquidated Damages										$ 1,112,000		$ 1,112,000
Debt Instrument Debt Default Percentage					140.00%
Mablife [Member]
Notes and Loans Payable [Line Items]
Loans Payable																	$ 600,000
Royalty Rate Percent of Net Sales																	0.60%
Purchase Obligation, Due in Fourth Year																$ 25,000
Purchase Obligation, Due in Fifth Year																35,000
Mablife [Member] | Secondary Patent Rights [Member]
Notes and Loans Payable [Line Items]
Purchase Obligation, Due in Second Year																15,000
Purchase Obligation, Due in Third Year																25,000
Purchase Obligation																$ 150,000
Subsequent Event [Member] | Series E Warrants [Member]
Notes and Loans Payable [Line Items]
Warrant, Exercise Price, Decrease			$ 0.20
Subsequent Event [Member] | Series E Preferred Stock [Member]
Notes and Loans Payable [Line Items]
Preferred Stock, Convertible, Conversion Price, Decrease			$ 0.20